Arcus Bios Reports Casdatifan Data Across ccRCC Treatment Lines
Arcus Bios presented updated ARC-20 data showing promising efficacy and manageable safety in first-, second- and late-line ccRCC settings. The headline reports a 50% first-line cORR.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.